Igene Biotechnology, Inc. (IGNE) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerIgene Biotechnology, Inc. (IGNE) trades at $0.00001. Igene Biotechnology, Inc. specializes in the development and commercialization of specialty ingredients for human and animal nutrition, focusing on natural astaxanthin. Sector: Materials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for IGNE: IGNE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Igene Biotechnology, Inc. (IGNE) Materials & Commodity Exposure
Igene Biotechnology, Inc. is a leader in the production of natural astaxanthin, catering to the nutritional needs of both human and animal markets, while offering research and development services in microbial strain improvement.
What Is the Investment Thesis for IGNE?
Igene Biotechnology, Inc. operates within a niche market that is experiencing increasing demand for natural ingredients in both human and animal nutrition sectors. The company's focus on natural astaxanthin provides a unique value proposition, as this ingredient is essential for enhancing the color and nutritional value of farmed fish, a growing segment within the aquaculture industry. With a gross margin of 25.7%, Igene demonstrates its ability to maintain profitability despite challenges, while its negative profit margin of -3.6% indicates potential areas for operational improvement. The global astaxanthin market is projected to grow significantly, driven by rising consumer awareness of health benefits associated with natural pigments. Furthermore, Igene's capabilities in microbial strain improvement and fermentation process development position it to capitalize on emerging trends in the nutraceutical space. However, investors should remain cautious of the company's current P/E ratio of -0.11, which reflects its ongoing financial challenges and the need for strategic initiatives to return to profitability.
Based on FMP financials and quantitative analysis
IGNE Key Highlights
Market Cap: $0.00B, indicating a currently unvalued position in the market.
- P/E Ratio: -0.11, highlighting ongoing financial challenges.
- Profit Margin: -3.6%, indicating potential areas for operational improvement.
- Gross Margin: 25.7%, showcasing the company's ability to maintain profitability in its niche.
- Beta: -23.34, suggesting extreme volatility in stock performance.
Who Are IGNE's Competitors?
IGNE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| SEED Origin Agritech Limited | $0.75 | +1.35% | $8.98M | — |
| BIOX Bioceres Crop Solutions Corp. | $0.34 | +0.06% | $21.6M | 37 5-pillar |
| BHST BioHarvest Sciences Inc. | $1.47 | -0.03% | $25.5M | — |
| AVD American Vanguard Corporation | $1.75 | +0.57% | $49.8M | 36 5-pillar |
| IPI Intrepid Potash, Inc. | $33.47 | +2.17% | $440M | 84 5-pillar |
| FMC FMC Corporation | $9.13 | +8.12% | $1.06B | 37 5-pillar |
| UAN CVR Partners, LP | $126.67 | +1.48% | $1.32B | 92 5-pillar |
| PURR Hyperliquid Strategies, Inc. | $12.93 | +8.75% | $1.60B | 40 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IGNE's Key Strengths?
Specialized expertise in natural astaxanthin production.
- Established relationships within the nutraceutical and feed industries.
- Strong R&D capabilities for product innovation.
What Are IGNE's Weaknesses?
Small workforce of 18 employees, limiting operational capacity.
- Negative profit margin indicating financial challenges.
- Dependence on a niche market for revenue.
What Are the Key Risks for IGNE?
Financial-distress signal — its Altman Z-Score of -22.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory changes impacting the agricultural inputs sector.
- Competition from other companies producing natural pigments.
- Financial instability due to negative profit margins.
What Threats Does IGNE Face?
- Intense competition within the agricultural inputs sector.
- Market volatility affecting ingredient prices.
- Regulatory challenges in food and feed industries.
What Are IGNE's Competitive Advantages?
- Established expertise in natural astaxanthin production.
- Strong R&D capabilities in microbial strain improvement.
- Unique analytical services for carotenoid verification.
What Does IGNE Do?
Founded in 1981, Igene Biotechnology, Inc. has established itself as a pioneering force in the agricultural inputs sector, specializing in the research, development, production, and commercialization of specialty ingredients aimed at enhancing human and animal nutrition. Originally known as IGI Biotechnology, Inc., the company rebranded to its current name in April 1986. Headquartered in Columbia, Maryland, Igene focuses on natural astaxanthin, a critical nutrient that serves as a pigment source for coloring farmed salmon and trout species. Beyond astaxanthin, the company also supplies a range of ingredients and finished products to the nutraceutical and feed industries. Igene's expertise extends to providing research and development services for microbial strain improvement and fermentation process development, scaling operations from shake flasks to pilot plants and commercial-sized fermentors. Additionally, the company offers analytical chemistry services for the identification and quantization of carotenoids in various food and feed products, including the verification of wild versus farm-raised salmonids. With a dedicated workforce of 18 employees, Igene Biotechnology is positioned to leverage its innovative capabilities to meet the growing demand for natural nutritional solutions in an increasingly health-conscious market.
What Products and Services Does IGNE Offer?
- Research and develop specialty ingredients for human and animal nutrition.
- Produce natural astaxanthin for coloring farmed salmon and trout.
- Supply nutraceutical and feed industry products.
- Provide research and development services for microbial strain improvement.
- Offer fermentation process development and scale-up services.
- Deliver analytical chemistry services for carotenoid identification and quantization.
How Does IGNE Make Money?
- Generate revenue through the sale of specialty ingredients and products.
- Offer research and development services to clients in the nutraceutical and feed industries.
- Provide analytical services to verify the quality and source of carotenoids.
What Industry Does IGNE Operate In?
The agricultural inputs industry is witnessing a shift towards natural and sustainable ingredients, driven by consumer demand for healthier food options and environmentally friendly practices. As aquaculture continues to expand globally, the need for natural colorants like astaxanthin is increasing, positioning Igene Biotechnology favorably within this growth trajectory. The global astaxanthin market is expected to reach approximately $1.5 billion by 2027, with a CAGR of around 15%. Igene's focus on research and development further enhances its competitive edge, allowing it to innovate and meet evolving market demands.
Who Are IGNE's Key Customers?
- Aquaculture businesses requiring natural colorants for fish.
- Nutraceutical companies seeking high-quality ingredients.
- Feed manufacturers looking for specialized additives.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Igene Biotechnology, Inc. stands at 5.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.0%, showing how much profit it generates from its asset base. A current ratio of 2.35 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Igene Biotechnology, Inc. operates in the Agricultural Inputs industry within the Basic Materials sector. It is headquartered in Columbia, US. The company is led by CEO Joseph L. Downs. IGNE has traded publicly since 1995.
Financial Health
Igene Biotechnology, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.97 places it in the distress zone, a signal of elevated financial risk.
IGNE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IGNE Latest News
-
Everything Solves DeFi with a Single Protocol
Business Insider · Aug 23, 2026
IGNE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IGNE.
Price Targets
Wall Street price target analysis for IGNE.
IGNE MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IGNE; grades run from A+ (80-100) to F (below 30).
Leadership: Joseph L. Downs
CEO
Joseph L. Downs has been at the helm of Igene Biotechnology, Inc. for several years, bringing extensive experience in biotechnology and business management. He has a strong background in developing innovative solutions for the agricultural sector, with a focus on enhancing product quality and operational efficiency. His leadership is characterized by a commitment to advancing the company's research and development initiatives.
Track Record: Under Joseph L. Downs' leadership, Igene has made significant strides in refining its production processes and expanding its product offerings. His strategic decisions have positioned the company to better meet the needs of its clients in the nutraceutical and feed industries.
IGNE OTC Market Information
The OTC Other tier refers to stocks that do not meet the criteria for higher tiers like OTCQX or OTCQB, often indicating lower visibility and liquidity. Companies in this tier may have less stringent reporting requirements, which can affect investor confidence.
- OTC Tier: OTC Other
- Less regulatory oversight compared to stocks listed on major exchanges.
- Potential for lower liquidity, making it difficult to buy or sell shares.
- Higher volatility due to lower trading volumes and investor interest.
- Review recent financial statements and disclosures.
- Assess the company's market position and competitive landscape.
- Evaluate management's track record and strategic vision.
- Investigate any legal or regulatory issues affecting the company.
- Consider the overall market conditions and trends in the agricultural inputs sector.
- Established company history since 1981.
- Focus on R&D and innovation in specialty ingredients.
- Partnerships with clients in the nutraceutical and feed industries.
What Investors Ask About Igene Biotechnology, Inc. (IGNE) — Materials
How does Igene Biotechnology, Inc. compare to competitors in its industry?
Igene Biotechnology, Inc. operates in a niche market focused on natural astaxanthin, which differentiates it from competitors like AgriFORCE Growing Systems Ltd. and American Green.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Data may be subject to change as new information becomes available.